(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of -16.36% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Sarepta Therapeutics's revenue in 2025 is $2,413,715,000.On average, 28 Wall Street analysts forecast SRPT's revenue for 2025 to be $226,864,259,855, with the lowest SRPT revenue forecast at $214,080,223,041, and the highest SRPT revenue forecast at $238,181,276,051. On average, 28 Wall Street analysts forecast SRPT's revenue for 2026 to be $168,288,222,322, with the lowest SRPT revenue forecast at $134,127,599,360, and the highest SRPT revenue forecast at $245,935,527,889.
In 2027, SRPT is forecast to generate $157,704,716,435 in revenue, with the lowest revenue forecast at $109,816,971,976 and the highest revenue forecast at $184,320,661,933.